SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma
SPARC to receive equity in Visiox along with other financial considerations
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
SDN-037
SPARC announces Phase 3 trial results of SDN-037 to treat inflammation and pain of ocular surgery
The primary efficacy measure was the proportion of subjects with an anterior chamber cell (ACC) grade of zero (0) on Day 15 (zero…